OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Myeloma and marrow adiposity: Unanswered questions and future directions	96
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	94
Editorial Board	92
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	91
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	65
Editorial Board	64
Editorial Board	59
Menopausal hormone therapy for the management of osteoporosis	52
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	52
Genetics of pubertal timing	47
Coronavirus disease 2019 and vitamin D	46
Regulation of bone mass: A splendid Orchestra	46
Gut microbiota and their metabolites in cardiovascular disease	45
Immune checkpoint inhibitor-related thyroid dysfunction	42
Sexual health and contraception in the menopause journey	41
Editorial Board	39
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	37
The role of androgens in transgender medicine	36
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	35
Remnant lipoprotein particles and cardiovascular disease risk	34
Editorial Board	34
Prenatal exposure to phthalate esters and its impact on child development	34
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	33
Haematological actions of androgens	33
Type 1 diabetes related to immune checkpoint inhibitors	31

Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	29
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	29
The effect of osteoporosis treatment on bone mass	29
Endocrine-disrupting chemicals and behaviour: A high risk to take?	27
Medullary thyroid cancer - An update	27
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	27
Non-oestrogen-based and complementary therapies for menopause	26
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	25
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	24
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	24
Metabolic complications and their mechanisms in patients with craniopharyngioma	24
Radioiodine therapy in the different stages of differentiated thyroid cancer	23
Hormone therapy for menopause and premature ovarian insufficiency	22
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	22
Pathophysiology of thyroid-associated orbitopathy	21
Immune checkpoint inhibitor-related hypophysitis	21
Approach to patients with elevated low-density lipoprotein cholesterol levels	21
Localization in primary hyperparathyroidism	20
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	20
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	20
Editorial Board	20
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Safety of androgen therapy in men with prostate cancer	20
Editorial Board	19
Editorial Board	19
The role of hormone therapy in urogenital health after menopause	19
Genotype-phenotype correlations in Graves’ disease	19
History of androgens and androgen action	19
Gut microbiome and bile acids in obesity-related diseases	19
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	19
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Genetics of anti-Müllerian hormone and its signaling pathway	18
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	18
Endocrine disrupting chemicals and bone	17
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	17
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	17
Preface	17
Anaplastic thyroid cancer: An update	17
Exercise and physical activity in individuals at risk of fracture	16
Paraneoplastic autoimmune hypophysitis: An emerging concept	16
Chemokines in thyroid autoimmunity	16
COVID-induced thyroid autoimmunity	16
The epidemiology of disorders of sex development	15
Covid-19 and endocrinology	15
Gut microbiome, prebiotics, intestinal permeability and diabetes complications	15
Editorial Board	15
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	15
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	15
Preface	15
Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity	15

The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	15
How best to monitor the specific side effects of medical treatments of Cushing’s disease	14
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	14
Surgical treatment of thyroid cancer: Established and novel approaches	14
Quality of life in thyroid cancer	13
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	13
SARS-CoV-2 infection and its effects on the endocrine system	13
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	13
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	13
Editorial Board	13
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	12
Menopausal hormone therapy in women with medical conditions	12
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	12
Adolescent primary hyperparathyroidism	12
Management of patients with statin intolerance	12
Endocrine abnormality in paraneoplastic syndrome	12
Regulation of bone mass in endocrine diseases including diabetes	12
Real-world value of cabergoline in the treatment of acromegaly	11
Long-term thionamide antithyroid treatment of Graves' disease	11
Androgen-based therapies in women	11
Genetics of 46,XY gonadal dysgenesis	11
Current medical treatment and perspective in gonadotroph tumors	10
Publisher's Note	10
COVID-19 vaccination and thyroiditis	9
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	9
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	9
Editorial Board	9
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	8
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	8
Editorial Board	8
Androgens part 2: Emerging areas	8
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	8
Burosumab: Current status and future prospects	8
Novel androgen therapies including selective androgen receptor modulators	8
Pituitary and SARS CoV-2: An unremitting conundrum	8
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	7
Heritable hyperparathyroidism: Genetic insights and clinical implications	7
Vitamin D deficiency or resistance and hypophosphatemia	7
Inherited fibroblast growth factor 23 excess	7
Associations of prenatal exposure to phthalates and one phthalate substitute with anthropometric measures in early life: Results from the German LIFE Child cohort study	7
The gut microbiota as a versatile immunomodulator in obesity and associated metabolic disorders	7
Neural regulation of bone marrow adipose tissue	7
Phthalates, ovarian function and fertility in adulthood	7
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	6
Morbidity and mortality in men: Role of androgens	6
Tumor-induced osteomalacia: An overview	6
Androgen therapy for women after menopause	6
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	5
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	5
Bone marrow adipose tissue: Role in bone remodeling and energy metabolism	5
Genetics of ovarian insufficiency and defects of folliculogenesis	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Pituitary dysfunction due to sports injuries	5
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	5
Innovative therapeutics in acromegaly	5
Management of non-hepatic distant metastases in neuroendocrine neoplasms	5
Marrow adipogenic lineage precursor: A new cellular component of marrow adipose tissue	5
Androgens, sports, and detection strategies for anabolic drug use	5
In utero exposure to phthalates and reproductive toxicity in rodents	5
New advances in menopause symptom management	5
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	5
Editorial Board	4
Clinical imaging of marrow adiposity	4
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	4
Developments in interventional management of hepatic metastases from neuroendocrine tumours	4
Thyroid hormone system disrupting chemicals	4
Editorial Board	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
Primary hyperparathyroidism	4
Editorial Board	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4